SG10201605729TA - Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy - Google Patents

Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Info

Publication number
SG10201605729TA
SG10201605729TA SG10201605729TA SG10201605729TA SG10201605729TA SG 10201605729T A SG10201605729T A SG 10201605729TA SG 10201605729T A SG10201605729T A SG 10201605729TA SG 10201605729T A SG10201605729T A SG 10201605729TA SG 10201605729T A SG10201605729T A SG 10201605729TA
Authority
SG
Singapore
Prior art keywords
nktcl
killer
diagnosis
therapy
natural
Prior art date
Application number
SG10201605729TA
Inventor
Bin Tean Teh
Soon Thye Lim
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Priority to SG10201605729TA priority Critical patent/SG10201605729TA/en
Publication of SG10201605729TA publication Critical patent/SG10201605729TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
SG10201605729TA 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy SG10201605729TA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG10201605729TA SG10201605729TA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG2011088002 2011-11-25
SG10201605729TA SG10201605729TA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Publications (1)

Publication Number Publication Date
SG10201605729TA true SG10201605729TA (en) 2016-08-30

Family

ID=54257023

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201402611WA SG11201402611WA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy
SG10201605729TA SG10201605729TA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201402611WA SG11201402611WA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Country Status (6)

Country Link
US (2) US20150292022A1 (en)
EP (1) EP2782562B1 (en)
JP (1) JP2015505669A (en)
CN (1) CN104220051B (en)
SG (2) SG11201402611WA (en)
WO (1) WO2013077814A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6416508B2 (en) * 2014-06-05 2018-10-31 公益財団法人がん研究会 Examination method of NK / T cell lymphoma
EP3551294B1 (en) * 2016-12-09 2022-02-16 ONK Therapeutics Limited Improved nk-based cell therapy
CN111479932A (en) * 2017-10-06 2020-07-31 新加坡保健服务集团有限公司 Method of treating lymphoma
CN108841869B (en) * 2018-05-31 2022-05-06 上海交通大学医学院附属瑞金医院 Construction method and application of zebra fish NK/TCL tumor model

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2397774A1 (en) * 2000-01-24 2001-07-26 Genzyme Corporation Jak/stat pathway inhibitors and the uses thereof
EP1984523A4 (en) * 2006-01-20 2010-03-03 Cell Signaling Technology Inc Mutant jak3 kinase in human leukemia

Also Published As

Publication number Publication date
EP2782562B1 (en) 2016-12-21
JP2015505669A (en) 2015-02-26
CN104220051B (en) 2017-04-19
US10378062B2 (en) 2019-08-13
WO2013077814A3 (en) 2013-10-10
CN104220051A (en) 2014-12-17
US20150292022A1 (en) 2015-10-15
WO2013077814A2 (en) 2013-05-30
SG11201402611WA (en) 2014-06-27
US20170029899A1 (en) 2017-02-02
EP2782562A2 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
IL222778A0 (en) Diabetes therapy
EP2596741A4 (en) Endoscope, and treatment instrument for endoscope
EP2779523A4 (en) Re-encryption system, re-encryption device, and program
GB2487355B (en) Processing apparatus, trace unit and diagnostic apparatus
EP2626000A4 (en) Endoscope adapter, endoscope processor, and endoscope system
EP2606811A4 (en) Bending operation device for endoscope, and endoscope
LT3831283T (en) Analyte sensor devices, connections, and methods
EP2611496A4 (en) Treatment methods
EP2757885A4 (en) Certain chemical entites, compositions, and methods
EP2825649A4 (en) Selective cell targeting using adenovirus and chemical dimers
PT2621569T (en) Treatment device
EP2501125A4 (en) Imaging device, imaging means and program
AP2014007420A0 (en) Integrated portable medical diagnostic system
EP2586495A4 (en) Respiration-induction device, respiration-induction program, and particle-beam therapy device
EP2652506A4 (en) The use anti-cxcl16 and anti-cxcr6 antibodies for the treatment or detecting cancer
EP2669639A4 (en) Indicator member, indicator unit and indicator instrument
HK1182444A1 (en) Biosensor
EP2596343A4 (en) Biosensor apparatuses and methods thereof
EP2521454A4 (en) Treatment with vb-201
PL2512547T3 (en) Balancing device, external medical functional device, treatment device
EP2837323A4 (en) Endoscope bending operation device, and endoscope equipped with such bending operation device
EP2621497A4 (en) Combination treatment for rosacea
EP2649921A4 (en) Medical device equipped with bowing-section, and endoscope
EP2737842A4 (en) Location detection device, capsule endoscope system, and capsule endoscope location detection program
EP2415408A4 (en) Treatment device